Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
How dying tumor cells get noticed: Besides killing tumor cells directly, some chemotherapies, such as anthracyclines, also activate the immune system to kill tumors. Vacchelli et al. discovered that in mice, anthracycline-induced antitumor immunity requires immune cells to express the protein formyl peptide receptor 1 (FPR1). Dendritic cells (DCs) near tumors expressed especially high amounts of FPR1. DCs normally capture fragments of dying tumor cells and use them to activate nearby T cells to kill tumors, but DCs lacking FPR1 failed to do this effectively. Individuals with breast or colon cancer expressing a variant of FPR1 and treated with anthracyclines showed poor metastasis-free and overall survival. Thus, FPR1 may affect anti-tumor immunity in people, too. Science , this issue p. 972
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This confirmed that Fpr1 deficient immune cells interacted much less with dying cancer cells treated with anthracyclines than immune cells expressing functional Fpr1 (Fig. 3B), explaining why Fpr1 deficiency leads to defective anticancer immune response and less efficient chemotherapy.”
From Microfluidics: A New Tool for Modeling Cancer–Immune Interactions (2016) · cites this paper as [62]
In the citing paper
“Recently, Vacchelli et al. identified a loss of-function mutation in the allele of the gene coding for formyl peptide receptor 1 (Fpr1) that correlated with poor survival in breast and colorectal cancer patients receiving adjuvant chemotherapy[62].”
From Microfluidics: A New Tool for Modeling Cancer–Immune Interactions (2016) · cites this paper as [62]
In the citing paper
“Extracellular ANXA1 reportedly acts as a DAMP and supports the activation of adaptive immune responses by engaging formyl peptide receptor 1 (FPR1) on DCs [876].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [876]
In the citing paper
“In line with these observations, RCD is not perceived as immunogenic when cancer cells are depleted of HMGB1 or ANXA1, as well as when the host lacks TLR4 or FPR1 [870, 876].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [876]
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Maere, S., Heymans, K., & Kuiper, M. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti551 · Cited by 4,155
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Self-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Self-citationMore powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Self-citationDenkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
Cited by
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Self-citationTumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Self-citationDendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574
The molecular machinery of regulated cell death
Tang, D., Kang, R., Berghe, T. V., Vandenabeele, P., & Kroemer, G. (2019) · Cell Research · doi:10.1038/s41422-019-0164-5 · Cited by 2,549
Self-citationThe immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Self-citationRoles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
“Mech-anistically, the expression of formyl-peptide receptor 1 on DCs favors the recognition and stable interaction with dying cancer cells followed by maturation, engulfing, and antigen presentation in breast and colorectal cancer (Vacchelli et al. 2015).”
BackgroundAntigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Immunogenic cell stress and death
Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353
Self-citationImmunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Self-citationMitochondrial metabolism and cancer
Porporato, P. E., Filigheddu, N., Pedro, J. M. B.-S., Kroemer, G., & Galluzzi, L. (2018) · Cell Research · doi:10.1038/cr.2017.155 · Cited by 1,273
Self-citationSpermidine in health and disease
Madeo, F., Eisenberg, T., Pietrocola, F., & Kroemer, G. (2018) · Science · doi:10.1126/science.aan2788 · Cited by 1,154
Self-citationConsensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
Self-citationDetection of immunogenic cell death and its relevance for cancer therapy
Fucikova, J., Kepp, O., Kasikova, L., Petroni, G., Yamazaki, T., Liu, P., Zhao, L., Spisek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03221-2 · Cited by 1,138
Self-citationCold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041
Self-citationMicrobiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883
Pattern Recognition Receptors and the Host Cell Death Molecular Machinery
Amarante-Mendes, G. P., Adjemian, S., Branco, L. M., Zanetti, L. C., Weinlich, R., & Bortoluci, K. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02379 · Cited by 749
Self-citationDendritic cell subsets in cancer immunity and tumor antigen sensing
Del Prete, A., Salvi, V., Soriani, A., Laffranchi, M., Sozio, F., Bosisio, D., & Sozzani, S. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-00990-6 · Cited by 644
DNA Damage and Repair Biomarkers of Immunotherapy Response
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D'Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 645
Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 607
Wang, C., Wang, J., Zhang, X., Yu, S., Wen, D., Hu, Q., Ye, Y., Bomba, H., Hu, X., Liu, Z., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3682 · Cited by 591
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 573
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
Self-citationNeutrophils in cancer carcinogenesis and metastasis
Xiong, S., Dong, L., & Cheng, L. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01187-y · Cited by 564
Linking cellular stress responses to systemic homeostasis
Galluzzi, L., Yamazaki, T., & Kroemer, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0068-0 · Cited by 515
Self-citationDamage-associated molecular patterns in cancer: a double-edged sword
Hernandez, C., Huebener, P., & Schwabe, R. F. (2016) · Oncogene · doi:10.1038/onc.2016.104 · Cited by 480
Microbiome and Anticancer Immunosurveillance
Zitvogel, L., Ayyoub, M., Routy, B., & Kroemer, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.001 · Cited by 478
Self-citationWu, M., Huang, Q., Xie, Y., Wu, X., Ma, H., Zhang, Y., & Xia, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01242-2 · Cited by 456
“In addition, chemotherapy can also induce local production of CXCL10, recruit T cells to the tumor bed [134] and enhance the differentiation of antitumor-specific CTLs [143].”
BackgroundNutrition, inflammation and cancer
Zitvogel, L., Pietrocola, F., & Kroemer, G. (2017) · Nature Immunology · doi:10.1038/ni.3754 · Cited by 446
Self-citationCell death in photodynamic therapy: From oxidative stress to anti-tumor immunity
Donohoe, C., Senge, M. O., Arnaut, L. G., & Gomes-da-Silva, L. C. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.07.003 · Cited by 442
Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses
Garg, A. D., & Agostinis, P. (2017) · Immunological Reviews · doi:10.1111/imr.12574 · Cited by 440
Fucikova, J., Spisek, R., Kroemer, G., & Galluzzi, L. (2021) · Cell Research · doi:10.1038/s41422-020-0383-9 · Cited by 400
Self-citationStress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity
Yang, H., Xia, L., Chen, J., Zhang, S., Martin, V., Li, Q., Lin, S., Chen, J., Calmette, J., Lu, M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0566-4 · Cited by 379
Self-citationMouse models in oncoimmunology
Zitvogel, L., Pitt, J. M., Daillère, R., Smyth, M. J., & Kroemer, G. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.91 · Cited by 343
Self-citationCell death in pancreatic cancer: from pathogenesis to therapy
Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00486-6 · Cited by 336
Self-citationTrial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Self-citationOptically-controlled bacterial metabolite for cancer therapy
Zheng, D.-W., Chen, Y., Li, Z.-H., Xu, L., Li, C.-X., Li, B., Fan, J.-X., Cheng, S.-X., & Zhang, X.-Z. (2018) · Nature Communications · doi:10.1038/s41467-018-03233-9 · Cited by 324
Biomarkers of response to PD-1/PD-L1 inhibition
Maleki Vareki, S., Garrigós, C., & Duran, I. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.06.001 · Cited by 318
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Liu, P., Zhao, L., Pol, J., Levesque, S., Petrazzuolo, A., Pfirschke, C., Engblom, C., Rickelt, S., Yamazaki, T., Iribarren, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09415-3 · Cited by 302
The role of dendritic cells in cancer and anti-tumor immunity
Marciscano, A. E., & Anandasabapathy, N. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101481 · Cited by 298
Heterogeneity of the tumor immune microenvironment and its clinical relevance
Jia, Q., Wang, A., Yuan, Y., Zhu, B., & Long, H. (2022) · Experimental Hematology & Oncology · doi:10.1186/s40164-022-00277-y · Cited by 300
Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend
Locy, H., de Mey, S., de Mey, W., De Ridder, M., Thielemans, K., & Maenhout, S. K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02909 · Cited by 279
Recent advances in microfluidic technologies for cell-to-cell interaction studies
Rothbauer, M., Zirath, H., & Ertl, P. (2018) · Lab on a Chip · doi:10.1039/c7lc00815e · Cited by 277
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Garg, A. D., More, S., Rufo, N., Mece, O., Sassano, M. L., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386829 · Cited by 276
Self-citationTipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death
Hayashi, K., Nikolos, F., Lee, Y. C., Jain, A., Tsouko, E., Gao, H., Kasabyan, A., Leung, H. E., Osipov, A., Jung, S. Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19970-9 · Cited by 274
Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies
Wang, Q., Ju, X., Wang, J., Fan, Y., Ren, M., & Zhang, H. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.08.028 · Cited by 264
Zhao, X., Yang, K., Zhao, R., Ji, T., Wang, X., Yang, X., Zhang, Y., Cheng, K., Liu, S., Hao, J., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.032 · Cited by 256
Switching from Apoptosis to Pyroptosis: Gasdermin-Elicited Inflammation and Antitumor Immunity
Tsuchiya, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010426 · Cited by 255
Mitophagy in Cancer: A Tale of Adaptation
Vara-Perez, M., Felipe-Abrio, B., & Agostinis, P. (2019) · Cells · doi:10.3390/cells8050493 · Cited by 251
“Although the involvement of mitophagy has not been formally proven, blocking the release of the mitochondrial DAMP N-formyl peptides during immunogenic cancer cell death elicited in response to anthracyclines and reduces anti-tumor immunity [308], suggesting a potential regulatory role for mitochondrial clearance, an…”
The dawn of vaccines for cancer prevention
Finn, O. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.140 · Cited by 254
Trial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239
Self-citationeIF2α phosphorylation is pathognomonic for immunogenic cell death
Bezu, L., Sauvat, A., Humeau, J., Gomes-da-Silva, L. C., Iribarren, K., Forveille, S., Garcia, P., Zhao, L., Liu, P., Zitvogel, L., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0044-9 · Cited by 241
Self-citationCell death, therapeutics, and the immune response in cancer
Hänggi, K., & Ruffell, B. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2023.02.001 · Cited by 237
Microfluidic modelling of the tumor microenvironment for anti-cancer drug development
Shang, M., Soon, R. H., Lim, C. T., Khoo, B. L., & Han, J. (2019) · Lab on a Chip · doi:10.1039/c8lc00970h · Cited by 227
Microfluidics: A New Tool for Modeling Cancer–Immune Interactions
Boussommier-Calleja, A., Li, R., Chen, M. B., Wong, S. C., & Kamm, R. D. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2015.12.003 · Cited by 224
“identified a loss of-function mutation in the allele of the gene coding for formyl peptide receptor 1 (Fpr1) that correlated with poor survival in breast and colorectal cancer patients receiving adjuvant chemotherapy[62].”
BackgroundTrial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., De Ruysscher, D., Tejpar, S., Vandenberghe, P., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 227
Self-citationThe Unfolded Protein Response in Immunogenic Cell Death and Cancer Immunotherapy
Rufo, N., Garg, A. D., & Agostinis, P. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.07.002 · Cited by 207
“In analogy to the pathogen-associatedmolecular patterns, DAMPs bind to pattern recognition receptors (including various TLRs) on the innate immune cells [e.g., professional antigen-presenting cells, like dendritic cells (DCs)] and favor the establishment of a productive interface between the dying cancer cells and the…”
BackgroundInfluentialBiomaterials for vaccine-based cancer immunotherapy
Zhang, R., Billingsley, M. M., & Mitchell, M. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.008 · Cited by 200
Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis
Lau, T. S., Chan, L. K. Y., Man, G. C. W., Wong, C. H., Lee, J. H. S., Yim, S. F., Cheung, T. H., McNeish, I. A., & Kwong, J. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0616 · Cited by 195
“In addition, ANXA1 released by dying tumor cells with anthracycline treatment requires interaction with the formyl peptide receptor 1 (FPR1) on dendritic cells to elicit T-cell–mediated antitumor immunity (10).”
BackgroundFormyl-Peptide Receptors in Infection, Inflammation, and Cancer
Weiß, E., & Kretschmer, D. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.08.005 · Cited by 187
Trial watch: IDO inhibitors in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777625 · Cited by 187
Self-citationContribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy
Yang, H., Ma, Y., Chen, G., Zhou, H., Yamazaki, T., Klein, C., Pietrocola, F., Vacchelli, E., Souquere, S., Sauvat, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1149673 · Cited by 185
Self-citationNguyen, M., De Ninno, A., Mencattini, A., Mermet-Meillon, F., Fornabaio, G., Evans, S. S., Cossutta, M., Khira, Y., Han, W., Sirven, P., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.12.015 · Cited by 184
Self-citationImmunogenic cell death in cancer: concept and therapeutic implications
Galluzzi, L., Kepp, O., Hett, E., Kroemer, G., & Marincola, F. M. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04017-6 · Cited by 179
Self-citationParlato, S., De Ninno, A., Molfetta, R., Toschi, E., Salerno, D., Mencattini, A., Romagnoli, G., Fragale, A., Roccazzello, L., Buoncervello, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01013-x · Cited by 181
Self-citationImmunological Mechanisms Underneath the Efficacy of Cancer Therapy
Galluzzi, L., Zitvogel, L., & Kroemer, G. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0197 · Cited by 175
“For instance, loss-offunction alleles of P2RX7 (55), TLR4 (52, 56), FPR1 (51, 56), and Toll-like receptor 3 (TLR3, which is involved in type I IFN signaling; ref.”
BackgroundSelf-citationPGE2 induced in and released by dying cells functions as an inhibitory DAMP
Hangai, S., Ao, T., Kimura, Y., Matsuki, K., Kawamura, T., Negishi, H., Nishio, J., Kodama, T., Taniguchi, T., & Yanai, H. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602023113 · Cited by 161
Deng, Y., Xia, X., Zhao, Y., Zhao, Z., Martinez, C., Yin, W., Yao, J., Hang, Q., Wu, W.-C., Zhang, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27349-7 · Cited by 174
Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death
Asadzadeh, Z., Safarzadeh, E., Safaei, S., Baradaran, A., Mohammadi, A., Hajiasgharzadeh, K., Derakhshani, A., Argentiero, A., Silvestris, N., & Baradaran, B. (2020) · Cancers · doi:10.3390/cancers12041047 · Cited by 164
Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy
Rapoport, B. L., & Anderson, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040959 · Cited by 164
Non-thermal plasma induces immunogenic cell deathin vivoin murine CT26 colorectal tumors
Lin, A. G., Xiang, B., Merlino, D. J., Baybutt, T. R., Sahu, J., Fridman, A., Snook, A. E., & Miller, V. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1484978 · Cited by 163
Research progress on morphology and mechanism of programmed cell death
Chen, Y., Li, X., Yang, M., & Liu, S. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06712-8 · Cited by 186
“…have been linked to the immunogenic mechanism of ICD: (1) calreticulin (CALR/CRT) [67], (2) adenosine triphosphate (ATP) [68], (3) high mobility group box protein B1 (HMGB1) [69], (4) type I interferon (IFN) [70], (5) cancer cell-derived nucleic acids [67, 71], and (6) annexin A1 (ANXA1) [72].”
BackgroundThe oncolytic peptide LTX-315 triggers immunogenic cell death
Zhou, H., Forveille, S., Sauvat, A., Yamazaki, T., Senovilla, L., Ma, Y., Liu, P., Yang, H., Bezu, L., Müller, K., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.47 · Cited by 157
Self-citationAnticancer metal drugs and immunogenic cell death
Terenzi, A., Pirker, C., Keppler, B. K., & Berger, W. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.06.021 · Cited by 151
Extracellular nucleosides and nucleotides as immunomodulators
Kepp, O., Loos, F., Liu, P., & Kroemer, G. (2017) · Immunological Reviews · doi:10.1111/imr.12571 · Cited by 188
Self-citationDahlgren, C., Gabl, M., Holdfeldt, A., Winther, M., & Forsman, H. F. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.04.014 · Cited by 147
Dendritic Cells and Cancer: From Biology to Therapeutic Intervention
Wylie, B., Macri, C., Mintern, J. D., & Waithman, J. C. (2019) · Cancers · doi:10.3390/cancers11040521 · Cited by 149
Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications
Musella, M., Manic, G., Maria, R. D., Vitale, I., & Sistigu, A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1314424 · Cited by 157
Self-citationStress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy
Radogna, F., & Diederich, M. F. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.02.006 · Cited by 149
Fucikova, J., Truxova, I., Hensler, M., Becht, E., Kasikova, L., Moserova, I., Vosahlikova, S., Klouckova, J., Church, S. E., Cremer, I., et al. (2016) · Blood · doi:10.1182/blood-2016-08-731737 · Cited by 135
Self-citationPro-necrotic molecules impact local immunosurveillance in human breast cancer
Stoll, G., Ma, Y., Yang, H., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1299302 · Cited by 156
Self-citationCross-priming in cancer immunology and immunotherapy
Luri‐Rey, C., Teijeira, Á., Wculek, S. K., de Andrea, C. E., Herrero, C., López‐Janeiro, Á., Rodriguez-Ruiz, M. E., Heras‐Murillo, I., Aggelakopoulou, M., Berraondo, P., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00785-5 · Cited by 162
“ICD releases mitochondrial formyl peptides and exposes annexin A1, which are detected by formyl peptide receptor 1 (FPR1), facilitating migration of DCs towards stressed tumour cells 320 .”
iRGD Modified Chemo‐immunotherapeutic Nanoparticles for Enhanced Immunotherapy against Glioblastoma
Kuang, J., Song, W. L., Yin, J., Zeng, X., Han, S. H., Zhao, Y., Tao, J., Liu, C., He, X., & Zhang, X. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201800025 · Cited by 133
Garg, A. D., Romano, E., Rufo, N., & Agostinis, P. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.5 · Cited by 151
Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152934 · Cited by 131
Chemotherapy remains an essential element of personalized care for persons with lung cancers
Hellmann, M. D., Li, B., Chaft, J. E., & Kris, M. G. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw271 · Cited by 145
Mechanisms of Regulated Cell Death: Current Perspectives
Santagostino, S. F., Assenmacher, C., Tarrant, J. C., Adedeji, A. O., & Radaelli, E. (2021) · Veterinary Pathology · doi:10.1177/03009858211005537 · Cited by 152
Biomarkers of Radiotherapy-Induced Immunogenic Cell Death
Vaes, R. D. W., Hendriks, L. E. L., Vooijs, M., & Ruysscher, D. D. (2021) · Cells · doi:10.3390/cells10040930 · Cited by 141
Thallinger, C., Füreder, T., Preusser, M., Heller, G., Müllauer, L., Höeller, C., Prosch, H., Frank, N., Świerzewski, R., Berger, W., et al. (2017) · Wiener klinische Wochenschrift · doi:10.1007/s00508-017-1285-9 · Cited by 147
Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity
Pedro, J. M. B., Sica, V., Martins, I., Pol, J. G., Loos, F., Maiuri, M. C., Durand, S., Bossut, N., Aprahamian, F., Anagnostopoulos, G., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.010 · Cited by 135
Self-citationBioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy
Ma, X., Yang, S., Zhang, T., Wang, S., Yang, Q., Xiao, Y., Shi, X., Xue, P., Kang, Y., Liu, G., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.016 · Cited by 125
TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves
Enot, D. P., Vacchelli, E., Jacquelot, N., Zitvogel, L., & Kroemer, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1462431 · Cited by 124
“Examples of its recent use include articles in Cancer Cell,2 Immunity,3 OncoImmunology4,5 and Science.6,7 We anticipate that its use will improve the statistical analyses of experimental tumor growth curves in an ever-expanding number of laboratories.”
Self-citationImmunosurveillance in clinical cancer management
Kroemer, G., Chan, T. A.-T., Eggermont, A. M. M., & Galluzzi, L. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21818 · Cited by 176
Self-citationImmunosuppression by Mutated Calreticulin Released from Malignant Cells
Liu, P., Zhao, L., Loos, F., Marty, C., Xie, W., Martins, I., Lachkar, S., Qu, B., Waeckel-Énée, E., Plo, I., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.11.004 · Cited by 130
Self-citationFabian, K. P., Wolfson, B., & Hodge, J. W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.728018 · Cited by 142
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B
Musella, M., Guarracino, A., Manduca, N., Galassi, C., Ruggiero, E., Potenza, A., Maccafeo, E., Manic, G., Mattiello, L., Rehim, S. S. A., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01290-3 · Cited by 129
“Accordingly, when CD24L ICD–CSCs or PAR AT3 cells were confronted with histocompat-ible splenocytes in ad hoc microfluidic devices 25 and then analyzed by videomicroscopy for their in vitro capability to recruit immune cells, only PAR cells were able to attract and stably interact with splenocytes…”
Self-citationLadoire, S., Enot, D., Senovilla, L., Ghiringhelli, F., Poirier-Colame, V., Chaba, K., Semeraro, M., Chaix, M., Penault-Llorca, F., Arnould, L., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1154244 · Cited by 117
Self-citationHighly Integrated Nano-Platform for Breaking the Barrier between Chemotherapy and Immunotherapy
Zheng, D., Chen, J., Zhu, J., Rong, L., Li, B., Lei, Q., Fan, J., Zou, M., Li, C., Cheng, S., et al. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b01432 · Cited by 117
Metadata
- Authors
- Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., Signore, M., De Ninno, A., Lucarini, V., Peschiaroli, F., Businaro, L., Gerardino, A., Manic, G., Ulas, T., Günther, P., Schultze, J. L., Kepp, O., Stoll, G., Lefebvre, C., Mulot, C., Castoldi, F., Rusakiewicz, S., Ladoire, S., Apetoh, L., Bravo-San Pedro, J. M., Lucattelli, M., Delarasse, C., Boige, V., Ducreux, M., Delaloge, S., Borg, C., André, F., Schiavoni, G., Vitale, I., Laurent-Puig, P., Mattei, F., Zitvogel, L., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Instituto Nazionale Tumori Regina Elena (IT)
- Gustave Roussy Cancer Campus, Villejuif, France.
- Istituto Superiore di Sanità (IT)
- Italian National Research Council, Institute for Photonics and Nanotechnology, Rome, Italy.
- National Research Council (IT)
- University of Bonn (DE)
- Centre Georges François Leclerc (FR)
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
- University of Siena (IT)
- Centre National de la Recherche Scientifique (FR)
- Université Paris-Saclay (FR)
- University of Rome Tor Vergata (IT)
- Université Paris Sorbonne Cité, UMRS 775, INSERM, Paris, France.
- Karolinska University Hospital (SE)
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Vacchelli, Erika
- Ma, Yuting
- Sistigu, Antonella
- Pietrocola, Federico
- Yang, Heng
- Adjemian, Sandy
- Signore, Michele
- Businaro, Luca
- Gerardino, Annamaria
- Manic, Gwenola
- Ulas, Thomas
- Günther, Patrick
- Schultze, Joachim L.
- Kepp, Oliver
- Stoll, Gautier
- Mulot, Claire
- Castoldi, Francesca
- Rusakiewicz, Sylvie
- Ladoire, Sylvain
- Lucattelli, Monica
- Delarasse, Cécile
- Boige, Valérie
- Ducreux, Michel
- Delaloge, Suzette
- Borg, Christophe
- André, Fabrice
- Schiavoni, Giovanna
- Vitale, Ilio
- Mattei, Fabrizio
- Zitvogel, Laurence
- Kroemer, Guido
- Venue
- Science
- Published
- 2015-11-20
- Volume
- 350
- Issue
- 6263
- Pages
- 972-978
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1911271782
- Cited by
- 452
- References
- 40
- Citations by year
- 2026: 25 · 2025: 25 · 2024: 29 · 2023: 51 · 2022: 38 · 2021: 50 · 2020: 58 · 2019: 47 · 2018: 45 · 2017: 40 · 2016: 42 · 2015: 1
- FWCI
- 20.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-LABX-0015, ANR-10-INBS-0001, ANR-10-IBHU-0001)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- FPR1, anthracycline chemotherapy, antitumor immunity, annexin A1, cancer cell death, T cell immunity, breast cancer, colorectal cancer, adjuvant chemotherapy, loss-of-function alleles, microfluidics, metastasis-free survival
- MeSH terms
- Alleles, Animals, Breast Neoplasms, Dendritic Cells, Female, Humans, Immunity, Innate, Leukocytes, Neoplasms, T-Lymphocytes, Colorectal Neoplasms, Chemotherapy, Adjuvant, Annexin A1, Anthracyclines, Polymorphism, Single Nucleotide, Receptors, Formyl Peptide, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.